First and only PARP inhibitor to improve invasive disease-free survival in patients
By applying digital technologies, pharma companies can significantly improve their operational and decision-making capabilities
Aurobindo Pharma Foundation endeavours to make a positive contribution to the underprivileged ommunities by supporting a wide range of socio-economic, educational, and health initiatives.
Tabrecta is the number one prescribed targeted therapy for advanced NSCLC with alterations leading to METex14 skipping globally
ANI’s Clorazepate Dipotassium Tablets are the generic version of the Reference Listed Drug (RLD) Tranxene.
Most recently, she served as chief human resources officer at Vyripharm Enterprises.
An interim analysis of this data shows no significant safety issues and a 91% seroconversion rate at Day 56.
Sanjay Verma of Akums Drugs & Pharmaceuticals, Manu Gupta of Cadila Pharmaceuticals, Rahul Borse of RPG Life Sciences, Krishna Sai T of Biocon and Amit Saluja of NASSCOM are speakers
V116 designed to target serotypes that account for 85% of all invasive pneumococcal disease in individuals aged 65 and over in the United States as of 2019
Guindo will be responsible for leading the development and implementation of the company’s long-term strategy for the Human Health portfolio.
Subscribe To Our Newsletter & Stay Updated
